Brief: Phathom Pharmaceuticals Resubmits Erosive Gerd New Drug Application To FDA
23/05/2023 22:24
May 23 (Reuters) - Phathom Pharmaceuticals Inc PHAT.O :
* PHATHOM PHARMACEUTICALS RESUBMITS EROSIVE GERD NEW DRUG
APPLICATION TO FDA
* PHATHOM PHARMACEUTICALS INC - ANTICIPATED FDA ACTION DATE
IN Q4
2023
* PHATHOM PHARMACEUTICALS INC - IF APPROVED, COMBINED LAUNCH
FOR
EROSIVE GERD AND H. PYLORI INDICATIONS PLANNED BEFORE YEAR END
Source text for Eikon: ID:nGNX3k1gdC
Further company coverage: PHAT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Phathom Pharmaceuticals
See all newsBrief: Phathom Pharma Provides Update On Litigation Filed By BDR Pharma Against FDA
Phathom Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Phathom Pharmaceuticals Q2 revenue beats on Voquezna prescription growth
Brief: Phathom Pharmaceuticals Q2 Net Income USD -17.582 Million
Phathom Pharmaceuticals Q1 revenue more than doubles, beats estimates